- AbbVie’s Humira gets a U.S. rival, but costs could stay high Reuters
- The End of Humira’s Monopoly The Dispatch
- Arthritis drug Humira’s two-decade reign ends as Amgen launches competing biosimilar Yahoo! Voices
- Amgen’s Amjevita ready to chip at Humira’s crown FiercePharma
- AbbVie Stock: The 20-Year Humira Monopoly Ends; So, What’s Next? | Investor’s Business Daily Investor’s Business Daily
- View Full Coverage on Google News
Source link